Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS System, the first FDA-cleared non-drug for pediatric attention...
NeuroThera Labs (TSXV: NTLX) has highlighted the expansion of the U.S. intellectual property (IP) portfolio through its ongoing collaboration with Clearmind Medicine (NASDAQ: CMND). As part of the collaboration, three U...
MAIA Biotechnology (NYSE American: MAIA) has received regulatory approval by the Spanish Agency for Medicines and Medical Devices and Portugal’s National Authority of Medicines and Health Products to begin...
Valion Bio (NASDAQ: VBIO) has announced the appointment of Dean Zikria as interim CEO, along with leadership changes aimed at strengthening alignment and execution as it advances Entolimod and evaluates strategic...
Medicus Pharma (NASDAQ: MDCX) has announced it will focus SkinJect development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular...
Castle Biosciences (NASDAQ: CSTL) is helping clinicians move beyond traditional pathology using gene expression profiling to reveal the underlying biology of a patient’s tumor, enabling more personalized treatment and...
Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...
BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to...
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic collaboration with closely held Radial, operator of the U.S.’s largest network of brain medicine clinics, to pursue the integration of Firefly’s...
Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate, for...